Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bolt Biotherapeutics's revenue per share for the
three
months ended in Jun. 2026 was €0.00.
Bolt Biotherapeutics's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was €2.22.
Warning Sign:
Bolt Biotherapeutics Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Bolt Biotherapeutics was 19.40% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 10.30% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 87.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Bolt Biotherapeutics's Revenue per Share or its related term are showing as below:
FRA:6LP0'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 10.3 Med: 94.9 Max: 206.3
Current: 10.3
During the past 8 years, Bolt Biotherapeutics's highest 3-Year average Revenue Per Share Growth Rate was 206.30% per year. The lowest was 10.30% per year. And the median was 94.90% per year.
FRA:6LP0's 3-Year Revenue Growth Rate is ranked better than 62.01% of 766
companies
in the Biotechnology industry
Industry Median: 3.35
vs FRA:6LP0: 10.30
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Bolt Biotherapeutics Revenue per Share Related Terms
Bolt Biotherapeutics Revenue per Share Historical Data
* Premium members only.
The historical data trend for Bolt Biotherapeutics's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6LP0 vs NCNA, CELZ, CURX: Revenue per Share Comparison
For the Biotechnology subindustry, Bolt Biotherapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bolt Biotherapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Bolt Biotherapeutics's PS Ratio falls into.
Bolt Biotherapeutics Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Bolt Biotherapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.22
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bolt Biotherapeutics (FRA:6LP0) has a Revenue per Share of €2.22 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Bolt Biotherapeutics and its competitors. According to the industry distribution chart, Bolt Biotherapeutics ranks #291 out of 766 companies in the Biotechnology industry, placing it in the top 38%.
Is Bolt Biotherapeutics' Revenue per Share too high?
Bolt Biotherapeutics' current Revenue per Share is €2.22. Based on the distribution chart, Bolt Biotherapeutics ranks #291 out of 766 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bolt Biotherapeutics has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Bolt Biotherapeutics' Revenue per Share compare to NCNA and CELZ?
According to the Biotechnology industry distribution chart, Bolt Biotherapeutics ranks #291 out of 766 companies for Revenue per Share. This puts Bolt Biotherapeutics in the upper half of its industry. The industry median Revenue per Share is 3.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 3.35, based on 766 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Bolt Biotherapeutics and its competitors. For the Biotechnology industry, the median Revenue per Share is 3.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bolt Biotherapeutics's current Revenue per Share is €2.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bolt Biotherapeutics stock overvalued right now?
Bolt Biotherapeutics (FRA:6LP0) has a current Revenue per Share of €2.22. The stock's GF Value™ is €8.22, compared to a current price of €5.18 — trading 37% below its estimated fair value. The current Revenue per Share is €2.22. Bolt Biotherapeutics' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Bolt Biotherapeutics (FRA:6LP0), the current Revenue per Share is €2.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bolt Biotherapeutics (FRA:6LP0) Overvalued in 2026?
Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued.
The current stock price of €5.18 is trading 37% below its estimated GF Value™ of €8.22.
Key valuation signals for FRA:6LP0:
Revenue per Share: €2.22
GF Value™: €8.22 vs. price of €5.18 (37% below fair value)
No single metric tells the full story. See the FRA:6LP0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
55GF Score
Get the complete analysis for FRA:6LP0
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6LP0 has been successfully added to your 
